Drugs / SSS17
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07025915 | Jun → Jul 2025 overdue | — | Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07024888 | Mar → May 2025 | — | Shenyang Sunshine Pharmaceutical Co., LTD. | Completed | No outcome recorded |
| Phase 1 | NCT04893187 | Jul 2021 → Dec 2022 | anemia due to chronic disorder | Shenyang Sunshine Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT04317833 | May 2020 → Jun 2021 | anemia due to chronic disorder | Shenyang Sunshine Pharmaceutical Co., LTD. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07007936 | Jul 2025 → Apr 2026 overdue | — | Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07014631 | Mar 2023 → Dec 2024 | anemia | Shenyang Sunshine Pharmaceutical Co., LTD. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSS17 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07024888 ↗ |
| Action | Inhibit | “through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH)” NCT04893187 ↗ |
| Modality | Small molecule | “SSS17 is a novel small molecule compound” NCT04317833 ↗ |
| Route | Oral | “administered by oral route” NCT04317833 ↗ |